Condition (MeSH)
Multiple System Atrophy
ClinicalTrials.gov lists 227 trials for Multiple System Atrophy or a narrower condition beneath it. MODAG GmbH has the most among industry and government lead sponsors, with 6.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase (log scale)
1 more section with rows
204 of the 227 trials are tagged with Multiple System Atrophy itself; the rest are tagged with a narrower condition beneath it.
When did Multiple System Atrophy trials start? (28)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 1 trial is registered to start in 2027 or later, and not listed here.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 2/3
- Phase 3
- Phase 4
- Not applicable
- Observational
Top of scale: 20
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 18 |
| 2025 | 18 |
| 2024 | 16 |
| 2023 | 16 |
| 2022 | 19 |
| 2021 | 20 |
| 2020 | 14 |
| 2019 | 15 |
| 2018 | 12 |
| 2017 | 9 |
Showing 10 of 28 earlier years.
Forecast of the full-year count, planned starts included, not rows of this table: about 22 trials starting in 2026 and about 20 in 2027, the average of the 24 months through September, counted as registered and carried forward. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 28 percent and ran about 20 percent low against the count later registered; forecasts made before the year began were off by about 39 percent and ran about 37 percent low against the count later registered. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.
Prediction, not a registry value: median of 36 months from start to primary completion across 41 trials still running at the 2026-10-09 snapshot; registered median of 30 months across 111 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Multiple System Atrophy trials in? (9)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 37 |
| Phase 1/2 | 4 |
| Phase 2 | 30 |
| Phase 2/3 | 3 |
| Phase 3 | 14 |
| Phase 4 | 3 |
| Not applicable | 59 |
| Observational | 74 |
| Expanded access | 3 |
How many Multiple System Atrophy trials are recruiting? (10)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 10 |
| Recruiting | 57 |
| Enrolling by invitation | 6 |
| Active, not recruiting | 18 |
| Available | 2 |
Showing 5 of 10 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Multiple System Atrophy trials? (6)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| MODAG GmbH | 6 |
| Alterity Therapeutics | 4 |
| H. Lundbeck A/S | 4 |
| National Institute of Neurological Disorders and Stroke (NINDS) | 4 |
| Chelsea Therapeutics | 3 |
Showing 5 of 6 sponsors.
Which drugs are being tested for Multiple System Atrophy? (6)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Droxidopa | 9 |
| Ampreloxetine | 3 |
| anle138b | 3 |
| Verdiperstat | 3 |
| NEBIVOLOL | 2 |
Showing 5 of 6 drugs.
Interventions as named in the registry (9)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Midodrine 2.5 mg tab | 4 |
| ATH434 | 3 |
| ALT001 | 2 |
| Low dose losartan | 2 |
| ONO-2808 | 2 |
Showing 5 of 9 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Multiple System Atrophy trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Urinary tract infection | 30 | 8 |
| Pneumonia | 29 | 8 |
| Syncope | 21 | 4 |
| Pneumonia aspiration | 19 | 6 |
| Fall | 18 | 6 |
Showing 5 of 10 adverse events.
Which publications cover Multiple System Atrophy? (110)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Development and Feasibility of a Mixed Virtual and in-Presence Therapeutic Education Program for Early Multiple System Atrophy Patients. | Movement disorders clinical practice | 2025 | Yes |
| Clinical Trial-Ready Patient Cohorts for Multiple System Atrophy: Coupling Biospecimen and iPSC Banking to Longitudinal Deep-Phenotyping. | Cerebellum (London, England) | 2024 | Yes |
| Neuropathologic Validation and Diagnostic Accuracy of Presynaptic Dopaminergic Imaging in the Diagnosis of Parkinsonism. | Neurology | 2024 | Yes |
| Health-related quality-of-life and burden for caregivers of individuals with neurogenic orthostatic hypotension. | Neurodegenerative disease management | 2023 | Yes |
| The Movement Disorder Society Criteria for the Diagnosis of Multiple System Atrophy. | Movement disorders : official journal of the Movement Disorder Society | 2022 | Yes |
Showing 5 of 110 publications.
Prevalence (39)
Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.
| Orphanet disease | Type | Class | Geography | Jurisdiction | Mapping relation |
|---|---|---|---|---|---|
| Multiple system atrophy | Point prevalence | 1-9 / 100 000 | United Kingdom | GB | Exact |
| Multiple system atrophy | Point prevalence | 1-9 / 100 000 | United Kingdom | GB | Exact |
| Multiple system atrophy | Point prevalence | 1-9 / 100 000 | United Kingdom | GB | Unspecified |
| Multiple system atrophy | Annual incidence | 1-9 / 1 000 000 | United States | US | Exact |
| Multiple system atrophy | Annual incidence | 1-9 / 1 000 000 | United States | US | Unspecified |
Showing 5 of 39 prevalence observations.
Rare-disease identity (2)
Shown in this order: exact, broader, narrower, other.
| Orphanet disease | ORPHA code | Relation | Source |
|---|---|---|---|
| Multiple system atrophy | 102 | Exact | Orphadata Science knowledge files, Product 1 |
| Multiple system atrophy | 102 | Exact | Orphanet Rare Disease Ontology (ORDO) |
Sub-conditions in MeSH (3)
MeSH descendants one level down with at least one trial, most trials first.
Not on this page
Not measured: delivery record.